期刊
JOURNAL OF NUCLEAR MEDICINE
卷 57, 期 8, 页码 1269-1275出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.116.175596
关键词
estrogen receptor; positron emission tomography; breast cancer; F-18-fluoroestradiol
Estrogen receptor (ER) expression in breast cancer is associated with a more favorable prognosis and is necessary for a response to endocrine therapies. Traditionally, ER expression is assessed by in vitro assays on biopsied tumor tissue. However, recent advances have allowed in vivo evaluation of ER expression with F-18-fluoroestradiol (F-18-FES) PET. Clinical studies have demonstrated the use of F-18-FES PET as a method for quantifying in vivo ER expression and have explored its potential as a predictive assay and method of assessing in vivo pharmacodynamic response to endocrine therapy. This review outlines the biology and pharmacokinetics of F-18-FES, highlights the current experience with F-18-FES in patient studies on breast cancer and other diseases, and discusses potential clinical applications and the possible future clinical use of F-18-FES PET.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据